On 7 October last, GLEAMER was awarded the e-Health Trophy in the Big Data/AI category of the e-Health Awards 2021, to the delight of its CEO and co-founder, Christian Allouche. “This award recognises the quality of our work but also underlines the fact that we are a key player in the digital health industry.”
In May this year, GLEAMER introduced BoneView 2.0. Two successful clinical trials in France and the United States have shown that on average, this solution reduces the number of fractures missed by radiologists and emergency physicians by 30%.
The product is particularly suitable for interpreting bone trauma X-rays. “This type of examination is extremely frequent, yet young radiologists do not always feel comfortable performing it. It is sometimes seen as tiresome and difficult,” explains Christian Allouche.
BoneView fits neatly into the radiologist’s environment and workflow. Drawing on deep learning technologies, GLEAMER’s engineers and researchers have designed algorithms bio-inspired by how the brain works. These algorithms have been trained using hundreds of thousands of images with pathology annotations. “We teach the algorithm to recognise these pathologies. The results found by AI are automatically sent to the image viewing system routinely used by the radiologist,” says the CEO. A square appears around the fracture, dislocation or other bone damage, for example.
“Within five years, the radiological profession and the way in which medical images are interpreted will have radically changed. This improves the quality of patient care and opens the way to new diagnostic applications. In the future, we will benefit the patient by predicting the onset of future pathologies,” says Christian Allouche, CEO and co-founder of GLEAMER.
BoneView is currently used in more than 200 hospitals and clinics. The deeptech startup based in Paris has succeeded in raising €10 million of finance to date. Accordingly, it is establishing itself as the world leader in the sector, and plans to enter the US market by the end of the year.
In parallel, it will launch a new product – ChestView – for interpreting chest X-rays, jointly developed with the Paris public hospitals authority (AP-HP). This new solution will detect nodules, pleural effusions and other alveolar foci.
